Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.
In vitro-transcribed mRNAs encoding physiologically important proteins have considerable potential for therapeutic applications. However, in its present form, mRNA is unfeasible for clinical use because of its labile and immunogenic nature. Here, we investigated whether incorporation of naturally modified nucleotides into transcripts would confer enhanced biological properties to mRNA. We found that mRNAs containing pseudouridines have a higher translational capacity than unmodified mRNAs when tested in mammalian cells and lysates or administered intravenously into mice at 0.015-0.15 mg/kg doses. The delivered mRNA and the encoded protein could be detected in the spleen at 1, 4, and 24 hours after the injection, where both products were at significantly higher levels when pseudouridine-containing mRNA was administered. Even at higher doses, only the unmodified mRNA was immunogenic, inducing high serum levels of interferon-alpha (IFN-alpha). These findings indicate that nucleoside modification is an effective approach to enhance stability and translational capacity of mRNA while diminishing its immunogenicity in vivo. Improved properties conferred by pseudouridine make such mRNA a promising tool for both gene replacement and vaccination.
Karikó
Katalin
K
Department of Neurosurgery, University of Pennsylvania, Room 371 Stemmler Hall, 36th & Hamilton Walk, Philadelphia, Pennsylvania 19104-6087, USA. kariko@mail.med.upenn.edu
Muramatsu
Hiromi
H
Welsh
Frank A
FA
Ludwig
János
J
Kato
Hiroki
H
Akira
Shizuo
S
Weissman
Drew
D
D000818:Animals; D002460:Cell Line; D005822:Genetic Vectors; D006801:Humans; D008156:Luciferases / Q000096:biosynthesis / Q000235:genetics; D051379:Mice; D014176:Protein Biosynthesis; D011560:Pseudouridine / Q000737:chemistry*; D012333:RNA, Messenger / Q000737:chemistry* / Q000276:immunology; D014158:Transcription, Genetic
D012333:RNA, Messenger; D011560:Pseudouridine; D008156:Luciferases
Immunity. 2005 Aug;23(2):165-75
16111635
Curr Opin Mol Ther. 2007 Oct;9(5):423-31
17932806
Immunity. 2005 Jul;23(1):19-28
16039576
Gene. 1995 Nov 20;165(2):233-8
8522182
Science. 2004 Mar 5;303(5663):1526-9
14976262
Synapse. 1994 Oct;18(2):128-51
7839312
Nature. 2001 Oct 18;413(6857):732-8
11607032
Immunol Rev. 2004 Jun;199:251-63
15233739
Nucleic Acids Res. 1995 Dec 25;23(24):5020-6
8559660
Nat Immunol. 2004 Jul;5(7):730-7
15208624
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):508-13
8552671
Science. 2004 Mar 5;303(5663):1529-31
14976261
RNA. 2004 Dec;10(12):1934-45
15547138
J Immunol Methods. 1999 Feb 1;223(1):77-92
10037236
Genet Vaccines Ther. 2006 May 29;4:4
16732888
Expert Opin Biol Ther. 2004 Aug;4(8):1285-94
15268662
Mol Genet Metab. 2003 Sep-Oct;80(1-2):148-58
14567964
J Biol Chem. 2004 Mar 26;279(13):12542-50
14729660
Biochim Biophys Acta. 1998 Mar 2;1369(2):320-34
9518670
Gene Ther. 2000 Jul;7(14):1171-82
10918485
Science. 1990 Mar 23;247(4949 Pt 1):1465-8
1690918
Biotechnol Bioeng. 2000 Sep 20;69(6):679-87
10918143
Handb Exp Pharmacol. 2008;(183):221-35
18071662
J Am Chem Soc. 1965 Sep 20;87(18):4209-10
4284810
Clin Chim Acta. 2003 Sep;335(1-2):27-32
12927681
Science. 2006 Nov 10;314(5801):994-7
17038590
Science. 2003 Oct 17;302(5644):415-9
14564000